Catalyst Pharmaceuticals(CPRX) Newsfilter·2025-01-21 13:19Core Insights - Catalyst Pharmaceuticals has announced the launch of FIRDAPSE® (amifampridine) Tablets 10 mg in Japan by its sub-licensee DyDo Pharma, aimed at improving muscle weakness in patients with Lambert-Eaton myasthenic syndrome (LEMS) [1][2] Company Overview - Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases, with a commitment to patient care and accessibility [6] - The company has a strong presence in the U.S. and is actively seeking to expand its global footprint through strategic partnerships [6] Product Information - FIRDAPSE is the only FDA-approved therapy for LEMS in adults and pediatric patients aged six years and older, characterized as a rare autoimmune disorder [2][3] - The mechanism of action for FIRDAPSE involves blocking potassium channels, enhancing neuromuscular transmission, and improving muscle function [3] Market Expansion - The launch of FIRDAPSE in Japan represents a significant step in expanding the geographic reach of Catalyst's product portfolio, enhancing access to life-changing therapies for patients in Japan [2][6] - DyDo Pharma, a wholly-owned subsidiary of DyDo Group Holdings, is responsible for the commercialization of FIRDAPSE in Japan [5]